IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.695
EU - Europa 9.095
AS - Asia 2.256
SA - Sud America 216
AF - Africa 31
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 15
Totale 23.331
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.650
GB - Regno Unito 2.488
IE - Irlanda 1.629
CN - Cina 1.283
UA - Ucraina 1.213
SE - Svezia 902
SG - Singapore 718
RU - Federazione Russa 670
DE - Germania 631
FR - Francia 598
IT - Italia 473
FI - Finlandia 295
BR - Brasile 182
VN - Vietnam 66
IN - India 39
CA - Canada 38
ES - Italia 38
NL - Olanda 32
TR - Turchia 27
BE - Belgio 25
HK - Hong Kong 22
AU - Australia 18
CI - Costa d'Avorio 18
AT - Austria 15
EU - Europa 15
CL - Cile 13
CZ - Repubblica Ceca 12
DK - Danimarca 11
IR - Iran 10
PL - Polonia 10
BD - Bangladesh 9
AR - Argentina 8
JP - Giappone 8
PK - Pakistan 8
RO - Romania 8
BG - Bulgaria 5
IQ - Iraq 5
MA - Marocco 5
NZ - Nuova Zelanda 5
TW - Taiwan 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
EC - Ecuador 4
HU - Ungheria 4
ID - Indonesia 4
JO - Giordania 4
LT - Lituania 4
OM - Oman 4
TH - Thailandia 4
VE - Venezuela 4
AL - Albania 3
AM - Armenia 3
BY - Bielorussia 3
CY - Cipro 3
IL - Israele 3
IM - Isola di Man 3
KZ - Kazakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BZ - Belize 2
CH - Svizzera 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KR - Corea 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MC - Monaco 2
MD - Moldavia 2
MW - Malawi 2
MX - Messico 2
MY - Malesia 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
DZ - Algeria 1
GY - Guiana 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
SY - Repubblica araba siriana 1
Totale 23.331
Salva come PNG Salva come JPEG
Città #
Southend 2.226
Fairfield 1.656
Dublin 1.613
Chandler 1.011
Jacksonville 993
Ashburn 903
Woodbridge 846
Wilmington 687
Seattle 655
Houston 613
Santa Clara 592
Cambridge 520
Nanjing 365
Ann Arbor 358
Princeton 333
Beijing 260
New York 234
Singapore 230
Siena 156
San Mateo 155
Boardman 137
Nanchang 123
San Diego 97
Helsinki 91
Moscow 89
Dong Ket 61
Hebei 53
Shenyang 53
Kunming 48
Shanghai 48
Norwalk 45
Tianjin 43
Changsha 41
Jiaxing 35
Málaga 32
Toronto 30
Lancaster 29
Los Angeles 29
London 27
Munich 27
Council Bluffs 26
Brussels 25
Ningbo 25
Hangzhou 24
Milan 23
Düsseldorf 22
Fremont 21
San Francisco 21
Jinan 20
Menlo Park 20
Zhengzhou 19
Abidjan 17
Hong Kong 17
Washington 17
Amsterdam 16
Auburn Hills 16
Nuremberg 14
Philadelphia 14
Redwood City 14
Frankfurt am Main 13
The Dalles 13
Guangzhou 12
Kansas City 12
São Paulo 12
Hounslow 11
Izmir 11
Changchun 10
Dallas 10
Dearborn 10
Lanzhou 10
Renton 10
Vienna 10
Belo Horizonte 9
Brno 9
Rome 9
Tappahannock 9
Delhi 8
Edinburgh 8
Falls Church 8
Kilburn 8
Santiago 8
Warsaw 8
Florence 7
Melbourne 7
Paris 7
Taizhou 7
Venezia 7
Fuzhou 6
San Jose 6
Sydney 6
Taastrup 6
Tokyo 6
Chicago 5
Istanbul 5
Las Vegas 5
Madrid 5
Mestre 5
Prescot 5
Sofia 5
Tashkent 5
Totale 16.248
Salva come PNG Salva come JPEG
Nome #
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 282
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 239
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 215
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 194
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 194
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 190
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 186
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 180
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 168
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 167
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 163
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 160
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 158
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 158
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 157
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 155
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 155
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 154
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 153
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 152
Quality of life in advanced colorectal cancer 151
Bioactivity of GM-CSF and IL-2 in cancer patients 148
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 147
70 Tumor associated hypercalcemia 147
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 147
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 145
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 145
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 145
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 144
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 144
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 144
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 144
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 144
Tumour associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 143
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 143
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 143
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 143
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 143
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 141
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 141
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 140
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 140
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 140
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 140
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 139
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 139
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 138
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 137
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 136
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 135
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 135
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer 135
Palliative chemotherapy for relief of subocclusive symptoms 134
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 134
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 133
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 133
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 132
Weekly chemotherapy in advanced prostatic cancer 132
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 132
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 132
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 131
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 131
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 131
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 130
Hepatoid gastric carcinoma. A case report 129
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 129
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 128
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 128
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 127
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. 127
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 125
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 125
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 125
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 124
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia. 124
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy 124
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 123
Weekly chemotherapy in advanced prostatic cancer 121
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 121
Seasonal variation in urinary excretion of cyclic AMP in healthy people 120
Weekly epirubicin in patients with hormone-resistant prostate cancer 120
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 119
GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. 119
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 119
In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse 117
Dendritic cell-cediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 117
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 116
Serum osteocalcin concentration in patients with prostatic cancer 116
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. 116
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 115
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase 115
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer 115
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 115
Models of active specific immuno-therapy of human malignancy bone metastases. 114
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 114
Treatment of bone metastases with dichloromethylene bisphosphonate 113
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 112
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care 112
Osteoblastic metastases: Metabolic and morphologic aspects 112
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. 112
Totale 14.019
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020868 0 0 0 0 0 0 0 0 0 432 109 327
2020/20214.016 196 408 98 349 306 588 155 600 482 238 329 267
2021/20222.434 180 310 201 195 103 62 102 97 133 264 243 544
2022/20233.640 240 211 455 543 360 805 62 327 396 59 121 61
2023/20242.336 116 60 171 73 63 771 781 39 3 47 48 164
2024/20252.515 112 286 310 266 547 212 75 229 397 81 0 0
Totale 23.478